With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects. Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies.
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:
- Type of Payload
- MMAE
- DM4
- Camptothecin
- DM1
- MMAF
- Others
- Type of Linker
- VC
- Sulfo-SPDB
- SMCC
- VA
- Hydrazone
- Others
- Target Indication
- Breast cancer
- Lymphoma
- Leukemia
- Urothelial cancer
- Lung cancer
- Ovarian cancer
- Others
- Target Antigen
- CD30
- HER2
- CD22
- CD33
- Others
- Technology Providers
- Seattle Genetics
- ImmunoGen
- StemCentRx
- Immunomedics
- Others
- Key Geographical Regions
- North America
- Europe
- Asia Pacific
The Antibody Drug Conjugates Market (5th Edition), 2019-2030.” report features the following companies, which we identified to be key players in this domain:
- Bristol Myers Squibb
- GlaxoSmithKline
- Incyte
- Novartis
- Trillium Therapeutics
Table of Contents
- Preface
2. Executive Summary
Introduction- Market Overview
- Company and Drug Profiles
- Key Therapeutic Areas
- Key Opinion Leaders
- Target Competitiveness Analysis
- Partnerships and Collaborations
- Funding and Investment Analysis
- Patent Analysis
- Academic Grants
- Key Commercialization Strategies
- Promotional Analysis
- Combination Therapies
- Novel Conjugation Technology Platforms
- Assessment of Non-Clinical Data, First in Human Dosing
- Cost Price Analysis
- Case Study: Contract Manufacturing of ADC
- Case Study: Companion Diagnostics for ADC Therapeutic
- Market Forecast and Opportunity Analysis
- Swot Analysis
- Conclusion
- Executive Insights
- Appendix 1: Tabulated Data
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
